STOK Stoke Therapeutics, Inc. Stock Quote

STOK [NASD]

Index	-	P/E	-	EPS (ttm)	-2.09	Insider Own	0.40%	Shs Outstand	36.76M	Perf Week	-19.44%
Market Cap	847.91M	Forward P/E	-	EPS next Y	-2.59	Insider Trans	-30.93%	Shs Float	19.91M	Perf Month	-4.84%
Income	-75.90M	PEG	-	EPS next Q	-0.73	Inst Own	53.00%	Short Float	12.38%	Perf Quarter	-13.85%
Sales	-	P/S	-	EPS this Y	-46.10%	Inst Trans	-4.38%	Short Ratio	16.91	Perf Half Y	-40.90%
Book/sh	6.46	P/B	3.53	EPS next Y	-8.00%	ROA	-27.70%	Target Price	60.44	Perf Year	-53.69%
Cash/sh	6.36	P/C	3.59	EPS next 5Y	-	ROE	-28.90%	52W Range	21.42 - 71.58	Perf YTD	-63.14%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-68.11%	Beta	-
Dividend %	-	Quick Ratio	20.60	Sales past 5Y	-	Gross Margin	-	52W Low	6.58%	ATR	1.86
Employees	79	Current Ratio	20.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	35.90	Volatility	7.55% 6.80%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-49.50%	Profit Margin	-	Rel Volume	0.92	Prev Close	24.90
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 08 BMO	Payout	-	Avg Volume	145.74K	Price	22.83
Recom	1.90	SMA20	-16.08%	SMA50	-10.42%	SMA200	-31.57%	Volume	134,226	Change	-8.31%

Nov-22-21

Upgrade

JP Morgan

Neutral → Overweight

$41

May-18-21

Initiated

UBS

Neutral

$35

May-10-21

Upgrade

Wedbush

Neutral → Outperform

Apr-26-21

Resumed

Credit Suisse

Outperform

$58

Feb-10-21

Downgrade

Wedbush

Outperform → Neutral

Dec-15-20

Resumed

H.C. Wainwright

Buy

$70

Dec-11-20

Reiterated

Needham

Buy

$48 → $56

Oct-23-20

Initiated

Cantor Fitzgerald

Overweight

$49

Sep-29-20

Resumed

JP Morgan

Neutral

$34

Sep-29-20

Initiated

Needham

Buy

$42

Dec-18-19

Initiated

Wedbush

Outperform

$31

Nov-12-19

Initiated

BTIG Research

Buy

$46

Oct-25-19

Initiated

H.C. Wainwright

Buy

$30

Jul-15-19

Initiated

JP Morgan

Overweight

$34

Jul-15-19

Initiated

Credit Suisse

Outperform

$35

Jul-15-19

Initiated

Cowen

Outperform

Jul-15-19

Initiated

Canaccord Genuity

Buy

$44

Nov-30-21 09:16AM	Moore Kuehn, PLLC Encourages Investors of Stoke Therapeutics, Inc. to Contact Law Firm Newsfile
Nov-22-21 07:20AM	Stoke Therapeutics Gets JPMorgan Upgrade Investing.com +10.50%
Nov-19-21 11:54AM	Stoke Therapeutics Announces Presentations from the Companys Dravet Syndrome Program at the American Epilepsy Society 2021 Annual Meeting Business Wire
Nov-08-21 07:00AM	Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates Business Wire
Nov-04-21 11:28AM	Notable Stoke Therapeutics Insider Trades $150K In Company Stock Benzinga
Nov-03-21 07:30AM	Stoke Therapeutics to Present at Upcoming Investor Conferences in November Business Wire +8.00%
Sep-22-21 04:30PM	Stoke Therapeutics to Present at the Cantor Global Healthcare Virtual Conference Business Wire +8.12%
Sep-21-21 12:46PM	Stoke Therapeutics Posts Encouraging Interim Safety Data From Early-Stage Dravet Syndrome Trial Benzinga +5.71%
06:59AM	Stoke Therapeutics Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome Business Wire
Sep-13-21 12:51PM	We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely Simply Wall St.
Aug-10-21 07:00AM	Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates Business Wire
Aug-03-21 08:00AM	Stoke Therapeutics to Present at Upcoming Investor Conferences in August Business Wire
May-18-21 07:30AM	Stoke Therapeutics to Present at the UBS Global Healthcare Virtual Conference Business Wire
May-10-21 07:30AM	Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates Business Wire
May-04-21 08:00AM	Stoke Therapeutics Presents New Data That Demonstrate Tango Antisense Oligonucleotides (ASOs) Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Autosomal Dominant Optic Atrophy (ADOA) Business Wire
Mar-30-21 07:30AM	Stoke Therapeutics Announces MHRA Authorization to Initiate Phase 1/2a Clinical Trial of STK-001 for Dravet Syndrome in the United Kingdom Business Wire
Mar-24-21 07:30AM	Stoke Therapeutics to Present at Upcoming Investor Conferences Business Wire -7.31%
Mar-15-21 09:39AM	We're Not Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Simply Wall St.
Mar-09-21 09:31AM	Ultragenyx's (RARE) IND for mRNA Therapy, UX053 Cleared by FDA Zacks
07:30AM	Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates Business Wire
Mar-04-21 07:30AM	Stoke Therapeutics to Present at the Barclays Global Healthcare Conference Business Wire
Feb-26-21 06:15AM	Mersana Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
06:00AM	Mersana Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update GlobeNewswire
Feb-19-21 08:00AM	Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2020 Financial Results and Business Updates GlobeNewswire
Feb-17-21 08:00AM	Mersana Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference GlobeNewswire
Jan-22-21 08:00AM	Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jan-19-21 08:00AM	Carla Poulson Joins Mersana Therapeutics as Chief Human Resources Officer GlobeNewswire
Jan-06-21 08:00AM	Mersana Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-05-21 10:00AM	Mersana Therapeutics Announces Corporate and Pipeline Updates and 2021 Goals and Anticipated Milestones GlobeNewswire
Jan-04-21 04:05PM	Stoke Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire -6.23%
Dec-25-20 03:06AM	Health Check: How Prudently Does Mersana Therapeutics (NASDAQ:MRSN) Use Debt? Simply Wall St.
Dec-17-20 08:00AM	Mersana Therapeutics to Host Virtual Analyst and Investor Event GlobeNewswire +8.03%
Dec-10-20 10:33PM	Is STOK A Good Stock To Buy Now? Insider Monkey
Dec-04-20 04:05PM	Stoke Therapeutics to Present at the Needham Virtual Epilepsy & Pain Specialty CNS Therapeutics Conference Business Wire
09:57AM	Stoke Therapeutics Announces Presentations Related to the Companys Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting Business Wire
Dec-02-20 04:05PM	Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -6.65%
Nov-30-20 08:00AM	Mersana Therapeutics Appoints Arvin Yang, M.D., Ph.D. as Senior Vice President and Chief Medical Officer GlobeNewswire
Nov-25-20 07:30AM	Stoke Therapeutics Announces Presentations Related to the Companys Work in Dravet Syndrome at the American Epilepsy Society 2020 Virtual Annual Meeting Business Wire
Nov-24-20 04:01PM	Stoke Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Nov-19-20 07:00PM	Stoke Therapeutics Announces Pricing of $97.5 Million Public Offering Business Wire
08:17AM	The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway Benzinga
Nov-18-20 04:02PM	Stoke Therapeutics Announces Proposed Public Offering Business Wire
Nov-12-20 07:38AM	Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates Business Wire
Nov-11-20 09:00AM	Mersana Therapeutics Reports Preclinical Data from Immunosynthen STING-Agonist ADC Platform and Pipeline GlobeNewswire
Nov-10-20 06:37AM	Analysts' Revenue Estimates For Mersana Therapeutics, Inc. (NASDAQ:MRSN) Are Surging Higher Simply Wall St. +9.52%
Nov-09-20 07:30AM	Stoke Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference Business Wire +6.65%
07:30AM	Mersana Therapeutics to Host Webinar Highlighting Immunosynthen STING-Agonist ADC Platform and Pipeline GlobeNewswire
06:15AM	Mersana Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
06:00AM	Mersana Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
Nov-05-20 10:51AM	Have Insiders Been Buying Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares? Simply Wall St.
Nov-04-20 08:00AM	Mersana Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare Conference GlobeNewswire
Nov-02-20 08:00AM	Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2020 Financial Results and Business Updates GlobeNewswire
07:30AM	Stoke Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare Conference Business Wire
Oct-14-20 05:05PM	Mersana Therapeutics to Present Preclinical Data from Immunosynthen STING-Agonist ADC Platform at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting GlobeNewswire
Oct-08-20 07:52AM	The Daily Biotech Pulse: Gilead, Lilly COVID-19 Treatment Supply Agreements, CareDx's Positive Preannouncement, Aziyo Biologics Debuts On Wall Street Benzinga
Oct-07-20 07:00AM	Stoke Therapeutics Announces Plans to Move Forward With Dosing of STK-001 in Children and Adolescents in its Ongoing Phase 1/2a MONARCH Study for Dravet Syndrome Business Wire +6.49%
Sep-29-20 12:23PM	Hedge Funds Keep Into Mersana Therapeutics, Inc. (MRSN) Insider Monkey
09:50AM	Benzinga's Top Upgrades, Downgrades For September 29, 2020 Benzinga
Sep-21-20 12:41PM	Why Mersana Therapeutics' (NASDAQ:MRSN) CEO Pay Matters Simply Wall St. -6.14%
Sep-17-20 06:00AM	Mersana Therapeutics Reports Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study GlobeNewswire
Sep-15-20 03:41PM	Top Biotech Stocks for Q4 2020 Investopedia -5.46%
11:48AM	Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Sep-10-20 08:00AM	Mersana Therapeutics to Present Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study at the 2020 ESMO Virtual Congress GlobeNewswire
Sep-09-20 07:30AM	Stoke Therapeutics to Present at Cantor Virtual Global Healthcare Conference Business Wire +7.95%
Sep-03-20 08:00AM	Mersana Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Sep-02-20 04:05PM	Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-31-20 08:00AM	Mersana Therapeutics Appoints Chuck Miller as Senior Vice President of Regulatory Affairs GlobeNewswire
Aug-26-20 02:00PM	Stoke Therapeutics Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine that Demonstrate Significant Improvements in Survival and Reductions in Seizure Frequency in a Dravet Syndrome Mouse Model Business Wire
Aug-17-20 07:30AM	Stoke Therapeutics Announces Appointment of Garry E. Menzel, Ph.D., to its Board of Directors Business Wire
Aug-11-20 12:25PM	Did Hedge Funds Make The Right Call On Mersana Therapeutics, Inc. (MRSN) ? Insider Monkey
08:00AM	Mersana Therapeutics Receives FDA Fast Track Designation for XMT-1536 for the Treatment of Patients with Platinum-resistant Ovarian Cancer GlobeNewswire
Aug-10-20 07:30AM	Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates Business Wire +5.15%
Aug-07-20 06:00AM	Mersana Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
Aug-04-20 12:19PM	Are Institutions Heavily Invested In Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Shares? Simply Wall St.
08:00AM	Mersana Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
07:30AM	Stoke Therapeutics to Present at Upcoming Investor Conferences in August Business Wire
Jul-31-20 08:00AM	Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2020 Financial Results and Business Updates GlobeNewswire
Jul-09-20 05:40AM	Stoke Therapeutics Announces Publication of Data in the Journal Nature Communications That Support the Companys Proprietary Approach to Addressing Severe Genetic Diseases by Precisely Upregulating Protein Expression Business Wire
Jul-08-20 04:15PM	Here is What Hedge Funds Think About Stoke Therapeutics, Inc. (STOK) Insider Monkey
Jun-24-20 12:27PM	Hedge Funds Never Loved Mersana Therapeutics, Inc. (MRSN) More Insider Monkey
Jun-04-20 08:00AM	Stoke Therapeutics Appoints Julie Anne Smith to its Board of Directors Business Wire -6.75%
May-15-20 07:00AM	Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates Business Wire
May-12-20 08:00AM	Stoke Therapeutics Presents Preclinical Data That Demonstrate In-Vitro and In-Vivo Target Engagement and Protein Upregulation in OPA1 Protein Deficiency, the Primary Cause of the Most Common Inherited Optic Nerve Disorder Business Wire
Mar-23-20 08:00AM	Stoke Therapeutics Reports Full Year 2019 Financial Results and Provides Business Updates Business Wire -11.66%
Feb-24-20 08:00AM	Stoke Therapeutics to Present at 40th Annual Cowen Health Care Conference Business Wire -8.93%
Jan-08-20 07:30AM	Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy PR Newswire
Jan-07-20 08:30AM	Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-23-19 08:30AM	Stoke Therapeutics Added to NASDAQ Biotechnology Index Business Wire -8.42%
Dec-19-19 04:51PM	Hedge Funds Are Selling Stoke Therapeutics, Inc. (STOK) Insider Monkey
Dec-08-19 10:00AM	Stoke Therapeutics Presents Preclinical Data on the Biodistribution, Target Engagement and Safety of STK-001 in Non-Human Primates That Support the Planned Clinical Development of STK-001 for the Treatment of Dravet Syndrome Business Wire
Dec-07-19 12:00PM	Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome Business Wire
Dec-06-19 02:23PM	Hedge Funds Love Liberty Tripadvisor (LTRPA) Way More Than These 3 Stocks Insider Monkey +15.78%
Nov-26-19 08:30AM	Stoke Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference TEST Business Wire Releases
08:30AM	Stoke Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference Business Wire
Nov-25-19 11:00AM	Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting TEST Business Wire Releases +6.22%
11:00AM	Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting Business Wire
Nov-22-19 06:43AM	Can The Uptrend Continue for Stoke Therapeutics? Zacks
Nov-12-19 08:00AM	Stoke Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update Business Wire -7.99%
Nov-05-19 08:30AM	Stoke Therapeutics to Present at Upcoming Investor Conferences in November Business Wire
Oct-28-19 02:12PM	Hedge Funds Have Never Been This Bullish On Stoke Therapeutics, Inc. (STOK) Insider Monkey

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nash Huw M.	COO & CBO	Nov 03	Option Exercise	2.19	1,900	4,161	1,900	Nov 03 06:05 PM
Nash Huw M.	COO & CBO	Nov 03	Sale	25.00	1,900	47,500	0	Nov 03 06:05 PM
Nash Huw M.	COO & CBO	Nov 01	Option Exercise	2.19	3,800	8,322	3,800	Nov 03 06:05 PM
Nash Huw M.	COO & CBO	Nov 01	Sale	23.54	3,800	89,456	0	Nov 03 06:05 PM
Nash Huw M.	COO & CBO	Oct 01	Option Exercise	2.19	5,700	12,483	5,700	Oct 04 05:51 PM
Nash Huw M.	COO & CBO	Oct 01	Sale	24.83	5,700	141,506	0	Oct 04 05:51 PM
Nash Huw M.	COO & CBO	Sep 01	Option Exercise	2.19	5,700	12,483	5,700	Sep 02 06:30 PM
Nash Huw M.	COO & CBO	Sep 01	Sale	26.00	5,700	148,223	0	Sep 02 06:30 PM
Nash Huw M.	COO & CBO	Aug 02	Option Exercise	2.19	5,700	12,483	5,700	Aug 04 07:41 PM
Nash Huw M.	COO & CBO	Aug 02	Sale	28.87	5,700	164,554	0	Aug 04 07:41 PM
Ticho Barry	Chief Medical Officer	Jul 13	Sale	32.75	43,166	1,413,654	130,895	Jul 15 07:29 PM
Nash Huw M.	COO & CBO	Jun 01	Option Exercise	2.19	575	1,259	575	Jun 03 05:48 PM
Nash Huw M.	COO & CBO	Jun 01	Sale	39.43	575	22,669	0	Jun 03 05:48 PM
Liau Gene	EVP Research & Preclinical Dev	Mar 02	Option Exercise	0.60	5,195	3,117	26,546	Mar 04 05:00 PM
Liau Gene	EVP Research & Preclinical Dev	Mar 02	Sale	63.05	5,195	327,546	21,351	Mar 04 05:00 PM
LEVIN ARTHUR A	Director	Mar 01	Option Exercise	0.53	12,500	6,576	12,500	Mar 03 05:10 PM
LEVIN ARTHUR A	Director	Mar 01	Sale	60.79	12,500	759,841	0	Mar 03 05:10 PM
Tulipano Stephen J	CFO	Feb 23	Option Exercise	4.48	5,000	22,400	5,602	Feb 24 05:15 PM
Tulipano Stephen J	CFO	Feb 23	Sale	58.60	5,000	292,992	602	Feb 24 05:15 PM
Tulipano Stephen J	CFO	Feb 22	Option Exercise	4.48	25,000	112,000	25,602	Feb 24 05:15 PM
Tulipano Stephen J	CFO	Feb 22	Sale	58.92	25,000	1,472,904	602	Feb 24 05:15 PM
TZIANABOS ARTHUR	Director	Feb 19	Option Exercise	2.19	10,000	21,900	10,000	Feb 23 05:28 PM
TZIANABOS ARTHUR	Director	Feb 19	Sale	60.67	10,000	606,652	0	Feb 23 05:28 PM
Nash Huw M.	COO & CBO	Jan 06	Sale	57.14	32	1,828	0	Jan 06 05:26 PM
Nash Huw M.	COO & CBO	Jan 04	Option Exercise	2.19	5,700	12,483	5,732	Jan 06 05:26 PM
Nash Huw M.	COO & CBO	Jan 04	Sale	58.97	5,700	336,157	32	Jan 06 05:26 PM
Kaye Edward M. MD	CEO	Dec 30	Option Exercise	0.60	10,000	6,000	10,000	Jan 04 06:33 PM
Liau Gene	EVP Research & Preclinical Dev	Dec 28	Option Exercise	0.60	8,000	4,800	21,500	Mar 04 05:00 PM
Liau Gene	EVP Research & Preclinical Dev	Dec 28	Sale	58.73	149	8,751	21,351	Mar 04 05:00 PM
Ticho Barry	Chief Medical Officer	Dec 21	Option Exercise	2.19	1,365	2,989	174,767	Dec 21 04:53 PM
Ticho Barry	Chief Medical Officer	Dec 21	Sale	57.62	1,365	78,654	173,402	Dec 21 04:53 PM
Nash Huw M.	COO & CBO	Dec 18	Option Exercise	0.60	8,015	4,809	8,015	Dec 18 09:08 PM
Kaye Edward M. MD	CEO	Dec 18	Sale	60.00	5,194	311,640	0	Dec 18 09:07 PM
Nash Huw M.	COO & CBO	Dec 18	Sale	60.00	8,015	480,900	0	Dec 18 09:08 PM
Nash Huw M.	COO & CBO	Dec 17	Option Exercise	0.60	41,985	25,191	41,985	Dec 18 09:08 PM
Kaye Edward M. MD	CEO	Dec 17	Sale	60.00	19,806	1,188,360	5,194	Dec 18 09:07 PM
Nash Huw M.	COO & CBO	Dec 17	Sale	60.00	41,985	2,519,100	0	Dec 18 09:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience